Decoding Akkermansia muciniphila Effector Biology: From Microbial Molecules to Host Outcomes
Authors:
- Amir Arsalan GhahariAGAmir Arsalan Ghahari
- Ainur SadykovaASAinur Sadykova
- Salim DavlatovSDSalim Davlatov
- Mukaddas XusanovaMXMukaddas Xusanova
- Gulrukh IndiaminovaGIGulrukh Indiaminova
- Furkat SobirovFSFurkat Sobirov
- Mirzamakhmud ShadmanovMSMirzamakhmud Shadmanov
- Umidjon MaxamatovUMUmidjon Maxamatov
- Patkhiddin NishonovPNPatkhiddin Nishonov
- Seyed Davar SiadatSSSeyed Davar Siadat
Open Access
- 29 July 2026
- journal article
- Published by Wiley in Microbiologyopen
- Vol. 15 (4)
Abstract
Akkermansia muciniphila is increasingly linked to host metabolic, immune, and neurobehavioral phenotypes, yet taxon‐level associations are often inconsistent across studies and disease contexts. This review advances an effector‐centered framework to explain how A. muciniphila acts through host‐facing molecules, including outer membrane and secreted proteins such as Amuc_1100 (pilus‐associated signaling, PAS) and P9, extracellular vesicles (EVs) and outer membrane vesicles (OMVs), and shed cell‐envelope fragments and lipids. We synthesize evidence spanning barrier biology, immunometabolic regulation, infection and inflammatory injury, cancer immunology, and microbiota–gut–brain axis research. Across models, effectors modulate the mucus and epithelial barrier to limit translocation and dampen Toll‐like receptor (TLR) signaling, but mucus‐active enzymes or antigenic epitopes may also create liabilities in susceptible hosts. Defined effectors can reproduce key whole‐cell effects: in high‐fat diet (HFD)/carbon tetrachloride (CCl4) liver injury, vesicle preparations matched or exceeded pasteurized bacteria; Amuc_1100 maps to immune reprogramming and barrier signaling; and P9 links microbial cues to glucagon‐like peptide 1 (GLP‐1) release. Key gaps include physiological dose realism, equivalence across colony‐forming units (CFU) and protein or vesicle doses, strain and culture‐condition dependence of effector expression, and limited human data for brain‐relevant endpoints. Effector‐defined preparations and engineered delivery systems may improve standardization and safety, but translation will require rigorous characterization, dose‐response validation, and mechanism‐linked biomarkers.Keywords
This publication has 99 references indexed in Scilit:
- An Integrated Engineering Approach to Creating Health‐Modulating PostbioticsMolecular Nutrition & Food Research, 2025
- Pasteurized Akkermansia muciniphila AKK PROBIO Attenuates Obesity Through Gut Microbiota-SCFA-GLP-1 Axis and Potential Involvement of AMPK/PPAR-α PathwayProbiotics and Antimicrobial Proteins, 2025
- Bacterial Extracellular Vesicles: Emerging Regulators in the Gut–Organ Axis and Prospective Biomedical ApplicationsCurrent Microbiology, 2025
- Akkermansia Muciniphila Alleviates Severe Acute Pancreatitis via Amuc1409‐Ube2k‐Foxp3 Axis in Regulatory T CellsAdvanced Science, 2025
- Heterologous expression of P9 from Akkermansia muciniphila increases the GLP-1 secretion of intestinal L cellsWorld Journal of Microbiology and Biotechnology, 2024
- Microbiota in cancer: molecular mechanisms and therapeutic interventionsMedcomm, 2023
- Akkermansia muciniphila Improves Depressive-Like Symptoms by Modulating the Level of 5-HT Neurotransmitters in the Gut and Brain of MiceMolecular Neurobiology, 2023
- A next-generation probiotic: Akkermansia muciniphila ameliorates chronic stress–induced depressive-like behavior in mice by regulating gut microbiota and metabolitesApplied Microbiology and Biotechnology, 2021
- Nutrient‐specific proteomic analysis of the mucin degrading bacterium Akkermansia muciniphilaProteomics, 2021
- The effect of bile acids on the growth and global gene expression profiles in Akkermansia muciniphilaApplied Microbiology and Biotechnology, 2020